Baird raised the firm’s price target on Regeneron (REGN) to $637 from $587 and keeps a Neutral rating on the shares. The firm updated its model following its Q3 beat which came with visibility into Eylea HD sBLA timelines.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $818 from $781 at Bernstein
- Regeneron price target raised to $865 from $815 at Guggenheim
- Regeneron price target raised to $627 from $543 at BofA
- Cautious Outlook on Regeneron Amid Eylea Erosion and Medicare Policy Risks
- Regeneron Pharmaceuticals Faces Financial Risks Amid Tariff and Trade Challenges